will tirzepatide go back on shortage list FDA confirms is still over, gives compounders a grace period Semaglutide and Tirzepatide No Longer

Early review allows simple adjustments before symptoms worsen

[2] These symptoms typically diminish over time as physiological adaptation occurs, but they can significantly impact nutritional intake during the initial treatment phases

More recently, the SELECT trial (2023) showed a 20% reduction in MACE with semaglutide 2.4 mg in people with obesity without diabetes establishing it as the first weight-loss medication with proven cardiovascular benefit in this population

The introduction of new therapiesparticularly those with novel mechanisms of action or broader symptom coveragemay fragment prescriber preferences and intensify competition for patient share